<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04176198</url>
  </required_header>
  <id_info>
    <org_study_id>BBI-TP-3654-102</org_study_id>
    <nct_id>NCT04176198</nct_id>
  </id_info>
  <brief_title>A Study of Oral TP-3654 in Patients With Myelofibrosis</brief_title>
  <official_title>A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients With Intermediate-2 and High-Risk Primary or Secondary Myelofibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sumitomo Dainippon Pharma Oncology, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sumitomo Dainippon Pharma Oncology, Inc</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase 1, multicenter, dose-escalation, open-label trial to assess safety,
      tolerability, pharmacokinetics and pharmacodynamics of TP-3654 in patients with
      intermediate-2 and high-risk primary or secondary MF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will enroll patients who have been previously treated and failed on a JAK
      inhibitor or ineligible to receive ruxolitinib or fedratinib.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 16, 2019</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the incidence of dose-limiting toxicities (DLTs) at escalated doses of TP-3654</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the incidence of treatment emergent adverse events</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the incidence of QT interval changes and morphology as assessed by intensive electrocardiogram (ECG) monitoring</measure>
    <time_frame>25 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Establish the pharmacokinetic (PK) parameters of TP-3654 by assessing Half-life (t½)</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Establish the pharmacokinetic (PK) parameters of TP-3654 by assessing Peak Plasma Concentration (Cmax)</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Establish the pharmacokinetic (PK) parameters of TP-3654 by assessing Time of Maximum concentration observed (tmax)</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Establish the pharmacokinetic (PK) parameters of TP-3654 by assessing Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess patients for any evidence of Preliminary activity by proportion of patients with responses in complete remission, partial remission, clinical improvement, progressive disease and stable disease</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Study potential pharmacodynamic (PD) markers of TP-3654</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluate exploratory biomarkers in peripheral blood samples and bone marrow biopsy samples</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Intermediate-2 Myelofibrosis</condition>
  <condition>High-Risk Primary Myelofibrosis</condition>
  <condition>High-Risk Secondary Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>TP-3654</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TP-3654</intervention_name>
    <description>Oral PIM Inhibitor</description>
    <arm_group_label>TP-3654</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients must meet all of the following inclusion criteria to be eligible:

          -  Confirmed pathological diagnosis of primary myelofibrosis (PMF) or post-PV-MF/post-ET-
             MF as per WHO diagnostic criteria and intermediate-2 or high-risk primary or secondary
             MF based on the Dynamic International Prognostic Scoring System (DIPSS)

          -  Previously treated with a JAKi and failed on a JAK inhibitor or are ineligible to be
             treated with Ruxolitinib or Fedratinib at the discretion of the investigator

          -  Grade ≥ 2 MF23, as confirmed by bone marrow biopsy within 12 weeks prior to Screening

        Fulfill the following laboratory parameters:

          -  Platelet count &gt; 50 X 109 /L, without the assistance of growth factors or platelet
             transfusions

          -  Absolute Neutrophil Count (ANC) ≥ 1 x 109/L without the assistance of granulocyte
             growth factors

          -  Hemoglobin ≥ 8 g/dL

          -  Peripheral blood blast count &lt; 10%

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤2

          -  Life expectancy ≥ 3 months

          -  Adequate renal function, as determined by clinical laboratory tests (serum creatinine
             &lt; 1.5 x upper limit of normal (ULN), and calculated creatinine clearance ≥60 mL/min)
             (Cockcroft-Gault)

          -  Adequate hepatic function (ALT/AST &lt; 2.5 x ULN, bilirubin &lt; 1.5 x ULN), and
             coagulation ([PT and PTT] &lt; 1.5 x ULN)

          -  Agree to provide 3 bone marrow biopsies during the study: at baseline or within 12
             weeks prior to enrollment, and every 6 months post-treatment.

          -  Splenomegaly during the screening period as demonstrated by splenic length ≥ 5 cm by
             palpation or spleen volume of ≥ 450 cm3 by Magnetic Resonance Imaging (MRI) or
             Computerized Tomography (CT) scan

          -  Show at least 2 symptoms measurable (score ≥ 1) using the MFSAF, v4.0.

        Patients meeting any one of these exclusion criteria will be prohibited from participating
        in this study:

          -  Received previous systemic antineoplastic therapy (including unconjugated therapeutic
             antibodies, toxin immunoconjugates, and alpha-interferon) or any experimental therapy
             within 14 days or 5 half-lives, whichever is shorter, before the first dose of study
             treatment.

          -  Major surgery within 2 weeks before the first dose of either study drug.

          -  Splenic irradiation within 6 months prior to Screening or prior splenectomy.

          -  AML, MDS, or peripheral blasts ≥ 10%.

          -  Prior autologous or allogeneic stem cell transplant at any time.

          -  Eligible for allogeneic bone marrow or stem cell transplantation. Experiencing
             electrolyte abnormalities of NCI CTCAE Grade ≥ 2 unless they can be corrected during
             screening and are deemed not clinically significant by the Investigator.

          -  History of congestive heart failure, myocardial infarction within the past 6 months
             prior to Cycle 1/Day 1; left ventricular ejection fraction &lt; 45% by echocardiogram or
             MUGA, unstable arrhythmia, or evidence of ischemia on electrocardiogram (ECG) within
             14 days prior to Cycle 1/Day 1.

          -  Corrected QT interval (using Fridericia's correction formula) of &gt; 450 msec in men and
             &gt; 470 msec in women.

          -  Central nervous system (CNS) cancer or metastases, meningeal carcinomatosis, malignant
             seizures, or a disease that either causes or threatens neurologic compromise (eg,
             unstable vertebral metastases).

          -  Other invasive malignancies within the last 3 years, except non-melanoma skin cancer,
             and localized cured prostate and cervical cancer

          -  Experienced portal hypertension or any of its complications.

          -  Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic
             therapy.

          -  Known bleeding diathesis or signs of uncontrolled active bleeding (hematuria, GI
             bleeding) other than self-limited causes of benign etiology that have been adequately
             investigated at the discretion of the Investigator.

          -  Requiring anticoagulation with aspirin &gt; 81mg daily, unfractionated heparin, low
             molecular weight heparin (LMWH), direct anti-thrombin inhibitors, or vitamin K
             antagonists (eg, warfarin).

          -  Severe chronic obstructive pulmonary disease with hypoxemia (defined as resting O2
             saturation of &lt; 90% breathing room air).

          -  Medical condition or have undergone significant surgery to the gastrointestinal tract
             that could impair absorption or that could result in short bowel syndrome with
             diarrhea due to malabsorption.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jennifer Szegda</last_name>
    <phone>617-674-6800</phone>
    <phone_ext>0802</phone_ext>
    <email>jszegda@bostonbiomedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>April Firstencel</last_name>
      <phone>216-286-2294</phone>
      <email>April.Firstencel@UHhospitals.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 8, 2019</study_first_submitted>
  <study_first_submitted_qc>November 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2019</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

